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Summary
Our previous work has shown the significant up-regulation of Il22 and
increased phosphorylation of signal transducer and activator of transcrip-
tion 3 (STAT3) as part of the mucosal inflammatory response to Clostrid-
ium difficile infection in mice. Others have shown that phosphorylation of
STAT3 at mucosal surfaces includes interleukin-22 (IL-22) and CD160-
mediated components. The current study sought to determine the potential
role(s) of IL-22 and/or CD160 in the mucosal response to C. difficile infec-
tion. Clostridium difficile-infected mice treated with anti-IL-22, anti-CD160
or a combination of the two showed significantly reduced STAT3 phosphor-
ylation in comparison to C. difficile-infected mice that had not received
either antibody. In addition, C. difficile-infected mice treated with anti-
IL-22/CD160 induced a smaller set of genes, and at significantly lower levels
than the untreated C. difficile-infected mice. The affected genes included
pro-inflammatory chemokines and cytokines, and anti-microbial peptides.
Furthermore, histopathological and flow cytometric assessments both
showed a significantly reduced influx of neutrophils in C. difficile-infected
mice treated with anti-IL-22/CD160. These data demonstrate that IL-22 and
CD160 are together responsible for a significant fraction of the colonic
STAT3 phosphorylation in C. difficile infection. They also underscore the
additive effects of IL-22 and CD160 in mediating both the pro-inflamma-
tory and pro-survival aspects of the host mucosal response in this infection.
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Introduction
Clostridium difficile is a Gram-positive, spore-forming,
anaerobic bacterium.1 It is the most prevalent cause of
nosocomial infectious diarrhoea in antibiotic-treated
patients.2–5 In antibiotic-treated individuals, C. difficile
spores can germinate, replicate as vegetative bacteria
and produce exotoxins, particularly TcdA and TcdB,
which act as the bacterium’s main virulence factors.
Both TcdA and TcdB are glucosyltransferases that irre-
versibly inactivate small GTPases of the Rho family.6,7
As a result, the epithelial actin cytoskeleton is depoly-
merized, the function of tight junctions is impaired,
and severe epithelial cell damage ensues.8–10 Infection
with C. difficile can lead to a broad range of clinical
outcomes, including asymptomatic colonization, mild
diarrhoea, severe pseudomembranous colitis and toxic
megacolon.2,11
In recent years, a number of groups have used an
approach in which mice are treated with antibiotics prior
to oral challenge with C. difficile to study the host
response to C. difficile infection. These studies have pro-
ven the higher susceptibility of MyD88/,12 TLR4/,13
NOD1/14 and ASC/15 mice to C. difficile infection,
and the protective effect of TLR5 stimulation against
acute C. difficile colitis.16 Based on the findings in
MyD88/, NOD1/ and ASC/ mice, it is now
believed that NOD1, MyD88 and interleukin-1b (IL-1b)
signalling enhance the expression of CXCL1 in the colon
in C. difficile-infected mice, thereby inducing neutrophil
influx to the site of infection.17
Recent work from our laboratory has shown that acute
infection of mice with C. difficile leads to pro-survival sig-
nalling as part of the mucosal inflammatory response.18
The infected mice display a significant up-regulation in
the expression of chemokines (including Cxcl1, Cxcl2 and
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Ccl2), numerous pro-inflammatory cytokines (including
Ifng, Il1b, Il6 and Il17f), as well as Il22 and a number of
anti-microbial peptides (including Defa1, Defa28, Defb1,
Slpi and Reg3g). In addition, they show significantly higher
phosphorylation of eukaryotic initiation factor 2a (eIF2a)
and signal transducer and activator of transcription 3
(STAT3) in their caeca and colons. These data prompted
us to speculate that either eIF2a phosphorylation or the
IL-22-pSTAT3-RegIIIc axis could potentially be used to
affect the nature of the host mucosal response to C. diffi-
cile infection.
The herpes virus entry mediator (HVEM), the first rec-
ognized entry route for herpes simplex virus (HSV), is a
cell surface molecule from the tumour necrosis factor
receptor superfamily.19 HVEM has been identified as a coli-
tis risk locus in humans,20 and plays a dual role in the
development of colitis in the mouse model.21,22 So far, as a
receptor, HVEM has been shown to bind five ligands: the
HSV envelope glycoprotein-D (gD)23; the tumour necrosis
factor-related cytokines LIGHT and lymphotoxin-a;24 and
the immunoglobulin superfamily members B and T lym-
phocyte attenuator (BTLA)25 and CD160.26 gD, BTLA and
CD160 bind HVEM through a binding site (CRD1) that is
distinct from the one for LIGHT (CRD2).27 Depending on
the ligand it binds, the cell types involved and the context
of engagement, HVEM can activate co-stimulatory or
co-inhibitory signalling pathways.28–30 The balance of the
pro-inflammatory and anti-inflammatory effects of HVEM
signalling in a specific case is the result of the interplay of
HVEM interactions with its various ligands on cells of both
the innate and adaptive immune systems.21 A more recent
report has focused on the role of HVEM in mucosal
defence against pathogenic bacteria.31 It shows the contri-
bution of HVEM to host defence against Citrobacter roden-
tium infection in the gut and Streptococcus pneumoniae
infection in the lung. More specifically, it provides evidence
that phosphorylation of STAT3 in mucosal epithelial cells
includes IL-22- and CD160-mediated components and
stipulates that HVEM signalling, through its ligand CD160,
acts cooperatively with IL-22 signalling to induce optimal
STAT3 activation for host defence at mucosal barriers.31
Based on our findings on the host response to C. diffi-
cile infection,18 and the recent report on the role of
HVEM/CD160 in host defence at mucosal barriers,31 we
devised the current study to examine the effects of IL-22
and CD160, and their potential interaction, on the mouse
mucosal response to C. difficile infection.
Materials and methods
Ethics statement
All animal experiments were conducted with the approval
of the University Committee on Use and Care of Animals
(UCUCA) at the University of Michigan. The University’s
animal care policies follow the Public Health Service pol-
icy on Humane Care and Use of Laboratory Animals.
The mice were housed in an AAALAC-accredited facility.
None of the conducted experiments involved the deliber-
ate induction of discomfort or injury. The physical condi-
tion and behaviour of the mice were assessed on a daily
basis. The mice were euthanized by CO2 asphyxiation in
compliance with the recommendations of the Panel on
Euthanasia of the American Veterinary Medical Associa-
tion.
Animals
Wild-type C57BL/6 mice obtained from Jackson Labora-
tories (Bar Harbor, ME) were used to establish a breeding
colony at the University of Michigan Medical School.
They were housed under specific pathogen-free conditions
and consumed clean food and water ad libitum. Male
mice at 5–8 weeks of age were used for the current set of
experiments.
Bacterial growth conditions and spore preparations
Clostridium difficile strain 630 (ATCC 1382) was cultured
in an anaerobic chamber (Coy Laboratory Products, Grass
Lake Charter Township, MI). For routine growth and
maintenance, the isolates were cultured on brain–heart
infusion broth supplemented with 05% yeast extract and
01% cysteine (BHIS) plates. Spore stocks for C. difficile
630 were produced as follows: An early spore preparation
was used to reconstitute vegetative cells by plating on
BHIS + 01% taurocholate. An isolated colony was used
to inoculate an overnight culture of Columbia broth.
Two millilitres of the overnight culture was then used to
inoculate 40 ml of Clospore medium,32 upon which the
culture was allowed to grow for 7 days. Cultures were
then washed at least four times in cold water to remove
vegetative cell debris. Spore stocks were stored in water at
4° until use.
Antibodies
Antibodies against IL-22 (clone IL22JOP) and CD160
(clone CNX46-3) were purchased from eBioScience (San
Diego, CA). The conjugated antibodies used for flow
cytometry, including the ones against CD11b (clone M1/
70), CD11c (clone HL3), CD45 (clone 30-F11), Ly6C
(clone AL-21) and Ly6G (clone 1A8), as well as an un-
conjugated antibody against FcRIII/II (clone 2.4G2), were
purchased from BD Biosciences (San Diego, CA) and
Biolegend (San Diego, CA). Those against phospho-
STAT3 (clone D3A7) and STAT3 (clone 79D7) were
obtained from Cell Signaling Technology (Danvers, MA).
Alkaline phosphatase-conjugated anti-rabbit antibody was
from Santa Cruz Biotechnology (Santa Cruz, CA).
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Administration of antibiotics, infecting mice with C.
difficile 630 and antibody treatment
5- to 8-week-old male wild-type C57BL/6 mice were either
left untreated (defined as untreated mice) or received cep-
hoperazone (05 g/l) in sterile drinking water for 5 days.
The mice receiving the antibiotic were then switched to
regular drinking water for 2 days. Afterwards, each of the
mice that had received cephoperazone was given 106 spores
of the C. difficile 630 strain by oral gavage.33 It should be
noted that we had used the VPI 10463 strain to infect mice
in our previous report.18 The decision to change the strain
in the current study was based on the finding that the 630
strain leads to a less severe and more prolonged course of
infection,33 and therefore could potentially provide broader
latitude for a given treatment to affect the outcome. The
C. difficile-infected mice consisted of four subgroups: the
first received neither anti-IL-22 nor anti-CD160 (CDI); the
second received anti-IL-22 (CDI + anti-IL-22); the third
received anti-CD160 (CDI + anti-CD160); and the fourth
received both anti-IL-22 and anti-CD160 (CDI + anti-
IL-22/CD160). The mice received the antibodies by intra-
peritoneal injection on days – 1, 1, 2 and 3. Each mouse
received 100 lg of the relevant antibody(ies) on each occa-
sion. All the animals were monitored for signs of disease
including diarrhoea, hunched posture and weight loss. All
the mice were killed 96 hr after the infection (Fig. 1).
Assessment of C. difficile colonization
A species-specific quantitative PCR was used to determine
C. difficile colonization in colon snips collected at the
time of necropsy. DNA extraction and C. difficile species-
specific quantitative PCR were performed as described
previously.34,35 Raw Ct values were normalized to a single
copy per genome host gene to generate DCt values.
34–36
DCt values were then converted to ‘detectable genomes/g
host tissue’ using a standard curve generated with known
amounts of vegetative C. difficile and colonic tissue. The
analytic limit of detection of the assay is ~ 103 genomes/g
of host tissue.
Enrichment of colonic leucocytes
Colonic leucocyte enrichment was performed as previ-
ously described,18 with certain modifications. The colon
of each mouse was excised, opened longitudinally and
washed in PBS to remove the faecal content. Afterwards,
each colon was incubated in calcium- and magnesium-
free Hanks’ balanced salt solution (HBSS) containing
25% fetal bovine serum, 1 mM dithiothreitol (DTT) and
5 mM EDTA for 20 min at 37°, washed and then incu-
bated in calcium- and magnesium-free HBSS containing
25% fetal bovine serum, 400 U/ml collagenase type 3
(Worthington Biochemical, Freehold, NJ) and 05 mg/ml
DNase I (Roche, Indianapolis, IN) for 60 min at 37°. The
digested samples were re-suspended in a 20% Percoll
solution (Sigma Aldrich, Milwaukee, WI) and centrifuged
at 900 g for 30 min at room temperature. The resulting
pellet was then washed and re-suspended in staining buf-
fer (HBSS containing 05% BSA and 01% sodium azide).
Flow cytometry
Cell suspensions prepared from colonic digests were
stained for flow cytometric analysis as previously
described.18 Briefly, colonic digests re-suspended in stain-
ing buffer were pre-blocked with unlabelled anti-FcRIII/II
Mice
5–8 weeks old wild-type
male C57BL/6
Switch to normal water
 Infect with 106
C. difficile 630 spores
Day –7 Day –1 Day 1 Day 3
Harvest
Day 4Day 2Day 0Day –2
Cephoperazone in
drinking water
Treatments for each group:
CDI + Anti-IL-22: Anti-IL-22
CDI + Anti-CD160: Anti-CD160
CDI + Anti-IL-22/CD160: Both
Anti-IL-22 and Anti-CD160
Treatments for each group:
CDI + Anti-IL-22: Anti-IL-22
CDI + Anti-CD160: Anti-CD160
CDI + Anti-IL-22/CD160: Both
Anti-IL-22 and Anti-CD160
Treatments for each group:
CDI + Anti-IL-22: Anti-IL-22
CDI + Anti-CD160: Anti-CD160
CDI + Anti-IL-22/CD160: Both
Anti-IL-22 and Anti-CD160
Treatments for each group:
CDI + Anti-IL-22: Anti-IL-22
CDI + Anti-CD160: Anti-CD160
CDI + Anti-IL-22/CD160: Both
Anti-IL-22 and Anti-CD160
Figure 1. Experimental timeline of the Clostridium difficile 630 infection.
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antibody. Afterwards, the cells were stained in a final vol-
ume of 100 ll in 96-well round bottom plates for
30 min. The cells were then washed (92) in the staining
buffer and re-suspended in BD Biosciences’ stabilizing fix-
ative. Data on the samples were acquired on a 3-laser
Canto II flow cytometer using FACSDIVA software (BD Bio-
sciences). The acquired data were analysed with the FLOW-
JO software (TreeStar, Ashland, OR). Leucocytes were
defined as cells with surface expression of CD45. Neu-
trophils were identified within this population by first
gating on the CD11bhigh CD11clow cells, followed by gat-
ing on Ly6Chigh events. The Ly6Ghigh cells within the
Ly6Chigh population were defined as neutrophils.
Histopathology
Colonic tissue from each mouse was placed in a histol-
ogy cassette and fixed with 10% neutral buffered forma-
lin for 24 hr and then transferred to 70% ethyl alcohol.
The cassettes were then paraffin-embedded, sectioned
and stained with haematoxylin & eosin for histopatho-
logical evaluation (McClinchey Histology Lab, Stock-
bridge, MI). Slides were examined on an Olympus BX45
light microscope (Olympus Corporation, Center Valley,
PA), and were scored by a board-certified veterinary
pathologist blinded to the experimental set-up. Neutro-
philic inflammation was assessed semi-quantitatively
according to a previously published scoring system.37
Briefly, neutrophilic inflammation scores were graded as
follows: (0) no inflammation; (1) minimal multifocal
neutrophilic inflammation (marginating or perivascular
neutrophils in submucosa, minimal intraepithelial and
proprial neutrophils); (2) moderate multifocal neutro-
philic inflammation (perivascular and interstitial neu-
trophils in submucosa, mild to moderate intraepithelial
and proprial neutrophils); (3) severe multifocal to coa-
lescing neutrophilic inflammation (perivascular and
increased interstitial neutrophils in submucosa with or
without extension to muscular wall, moderate intraepi-
thelial neutrophils); and (4) same as score 3 with
abscesses.
Representative images were taken with a QImaging
MicroPublisher RTV 5.0 camera (QImaging Corporation,
Surrey, BC), at 9100 and 9400 magnifications. Images
were acquired using QCAPTURE SUITE PLUS (QImaging Cor-
poration). Image processing and composite construction
were performed in ADOBE PHOTOSHOP (San Jose, CA).
Image processing was limited to global adjustments of
brightness, contrast, exposure, sharpness, image size and
colour balance as needed.
Western blot analysis
Immunoblotting was performed as previously
described.18 Briefly, colon snips obtained from untreated
mice and the ones in each of the other experimental
groups were homogenized on ice with a rotor/stator-type
homogenizer (Biospec Products, Bartlesville, OK) while
immersed in ice-cold modified RIPA buffer supple-
mented with HALT protease and phosphatase inhibitor
cocktail (Thermo Fisher, Rockford, IL). All tissue lysates
were subjected to two rounds of centrifugation at
10 000 g for 10 min. The bicinchoninc acid protein
assay (Thermo Fisher) was used to determine the pro-
tein concentration of each of the cleared lysates. Thirty
micrograms of each colon lysate protein was boiled for
5 min in reducing sample buffer containing DTT and
resolved by SDS–PAGE electrophoresis, transferred to
PVDF membranes and probed with the indicated anti-
bodies. The membranes were exposed to enhanced
chemifluorescence substrate (GE Healthcare, Piscataway,
NJ), followed by scanning on a Typhoon Trio+ imaging
system (GE Healthcare) to obtain a digital image of the
probed protein. The bands were then quantified with IM-
AGEQUANT software (GE Healthcare).
Quantification of mRNA levels using custom-made
quantitative RT-PCR cards
Quantification of mRNA levels was performed as previ-
ously described.18 Briefly, colon snips obtained from
untreated mice and the ones in each of the other
experimental groups were homogenized with a rotor/
stator-type homogenizer while immersed in TRIzol
RNA reagent (Life Technologies, Grand Island, NY).
The TRIzol RNA reagent and the RNeasy Mini kit
(Qiagen, Valencia, CA) were used in successive steps to
isolate RNA from the colon samples, each according to
its manufacturer’s instructions. An Agilent Bioanalyser
(Agilent Technologies, Palo Alto, CA) and a Nanodrop
instrument (Thermo Fisher) were used to determine
the quality and concentration of each RNA isolate
respectively. Complementary DNA (cDNA) was
generated from each RNA sample using the RT2 First
Strand kit (Qiagen). Expression levels of the genes
under study were determined by using a set of mouse
RT2 Profiler PCR cards (Qiagen), custom-made to con-
tain eight replicate sets of 48 primer pairs (Table 1).
Each well of the replicate sets was loaded with 5 ng of
cDNA reaction product. Each card was run on a
LightCycler 480 real-time PCR system (Roche). The rel-
ative RNA expression levels were inferred from the Ct
values.
Statistical analyses
For the C. difficile colonization assay, the difference
between the untreated mice with the CDI, the CDI + anti-
IL-22, the CDI + anti-CD160, and the CDI + anti-IL-22/
CD160 groups of C. difficile-infected mice was evaluated
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for significance by using the Kruskal–Wallis test followed
by Dunn’s multiple comparisons test with significance set
at P ≤ 005. For both STAT3 phosphorylation, and scor-
ing of neutrophilic inflammation, the difference between
the untreated mice with the CDI, the CDI + anti-IL-22,
the CDI + anti-CD160, and the CDI + anti-IL-22/CD160
groups of C. difficile-infected mice was evaluated for sig-
nificance by using one-way analysis of variance with Geis-
ser–Greenhouse correction followed by Fisher’s least
significant difference test with significance set at P ≤ 005.
The quantitative RT-PCR data acquired with custom-
made cards were normalized as previously described.18,38
The normalized numbers were used to calculate DCt val-
ues for each gene by deducting the geometric mean of
the Actb and Gapdh Ct values of each sample from the Ct
value of each gene in that sample.39 The SAM (Statistical
Analysis for Microarray) software developed by Tusher
and colleagues40 was then used to compare the expression
levels of each gene between the colons of different groups
of mice. In each case, genes for which false discovery rate
≤ 005 were considered significant.41 All the significant
genes with at least a twofold change in expression were
defined as up- (or down)-regulated.
Results
C. difficile 630 colonizes mice pre-treated with
cephoperazone
The timeline and details of the experiment, as described
in the Materials and methods section, are depicted in
Fig. 1. Following pre-treatment with cephoperazone, the
mice received an oral gavage of 106 spores of C. difficile
strain 630 on day 0. All the C. difficile-infected mice
showed a gradual decline in weight over the course of
infection (Fig. 2a). A C. difficile-specific quantitative PCR
assay showed the significant colonization of the colons of
all the C. difficile-infected mice with C. difficile at the end
of the experimental period, i.e. day 4 of infection
(Fig. 2b). There was no significant difference in C. difficile
load between C. difficile-infected mice that had not
received either anti-IL-22 or anti-CD160 (CDI), C.
Table 1. List of evaluated genes. The groupings of the genes is based on either the structural relationship of the particular set of genes, and/or
on their established (or purported) functions
Chemokines Ccl2 Ccl3 Ccl4 Cxcl1 Cxcl2 Cxcl9 Cxcl10
Cytokines and related molecules Il1b Il4 Il6 Il10 Il12a Il13 Il17a Il17f
Il22 Il23a Il25 Ifng Tgfb1 Tnfa Tslp
Anti-microbial peptides Camp Defa1 Defa4 Defb1 Defb3 Reg3g Slpi
Nod-like receptors Nod1 Nod2
Short-chain fatty acid receptors Ffar2 Ffar3 Gpr35
Tight junction and adhesion proteins Cldn1 Cldn2 Epcam Tjp1 Tjp2
Miscellaneous Actb Arg1 Gapdh Hgf Mgdc Mpo Nos2 Retnla Shh
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Figure 2. Reduction in weight of Clostridium difficile-infected mice, and significant colonization of their colons with C. difficile. (a) Reduction in
weight of C. difficile-infected mice in comparison to their untreated counterparts (n = 8 for each group) from two sets of experiments. (b) A spe-
cies-specific quantitative PCR assay was used to quantify C. difficile colonization in the colons (n = 8 in each group) of untreated mice, C. diffi-
cile-infected mice that had not received either anti-interleukin-22 (IL-22) or anti-CD160 (CDI), CDI + anti-IL-22 mice, CDI + anti-CD160 mice,
and CDI + anti-IL-22/CD160 mice from two sets of experiments. Each bar represents the mean  SEM of the C. difficile load. ★ denotes a sig-
nificant difference in colonization with the untreated mice, i.e. a P value of ≤ 005 for the Dunn’s post hoc test. The analytic limit of detection of
the assay is ~ 103 genomes/g of host tissue.
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difficile-infected mice that had received anti-IL-22
(CDI + anti-IL-22), C. difficile-infected mice that had
received anti-CD160 (CDI + anti-CD160), and C. diffi-
cile-infected mice that had received both anti-IL-22 and
anti-CD160 (CDI + anti-IL-22/CD160).
Anti-IL-22, anti-CD160 and combined anti-IL-22/
CD160 treatment significantly reduce STAT3
phosphorylation in C. difficile-infected mice
We have previously shown that C. difficile strain VPI
10463 induces phosphorylation of STAT3 in the colons of
infected mice.18 To examine the effect of infection with
C. difficile 630 on STAT3 phosphorylation levels, colonic
protein lysates from untreated mice, CDI mice,
CDI + anti-IL-22 mice, CDI + anti-CD160 mice, and
CDI + anti-IL-22/CD160 mice were probed for the phos-
phorylation levels of STAT3. Consistent with our previous
findings, colons of CDI mice showed a significant
increase in STAT3 phosphorylation in comparison to
untreated mice (Fig. 3). CDI + anti-IL-22 mice,
CDI + anti-CD160 mice, and CDI + anti-IL-22/CD160
mice also had significantly higher levels of phosphorylated
STAT3 than the untreated mice.
We then analysed the effect of antibody treatment on
STAT3 phosphorylation in C. difficile-infected mice.
Based on this analysis, CDI + anti-IL-22 mice,
CDI + anti-CD160 mice, and CDI + anti-IL-22/CD160
mice all had significantly lower levels of phosphorylated
STAT3 than the CDI mice (Fig. 3).
Combined anti-IL-22/CD160 treatment significantly
alters the mucosal gene expression pattern in
response to C. difficile infection
In our previous study, we had used a quantitative
RT-PCR approach to examine the host mucosal response
in mice infected with the VPI 10463 strain of C.
difficile.18 This had shown a significant increase in the
expression of a number of chemokines, pro-inflammatory
cytokines, as well as Il22 and a number of anti-microbial
peptides at the sites of infection. We adopted a similar
approach in the current work, where we examined the
expression patterns of 45 genes (see Table 1) in the colons
of mice infected with C. difficile 630 (CDI). The infected
mice displayed a significant up-regulation of the chemo-
kines Ccl2, Ccl3, Ccl4, Cxcl1, Cxcl2, Cxcl9 and Cxcl10; the
cytokines Ifng, Il1b, Il6, Tnfa, Il12a, Il22 and Il25; the
anti-microbial peptides Defa1, Defb1, Reg3g and Slpi; as
well as Arg1, Ffar3, Mpo and Nos2 in comparison to the
untreated mice (Fig. 4a); a pattern closely comparable to
our previous findings.18
Having established that the gene expression pattern in
the colons of mice infected with C. difficile 630 (CDI) is
closely comparable to that of mice infected with C. diffi-
cile VPI 10463,18 we proceeded to evaluate the effects of
anti-IL-22, anti-CD160 and anti-IL-22/CD160 treatments
on the mice infected with C. difficile 630 (CDI). To
examine the matter closely, we performed a statistical
comparison between the genes expressed in the CDI
mice and each of the following groups: CDI + anti-IL-
22 mice (Fig. 4b), CDI + anti-CD160 mice (Fig. 4c),
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Figure 3. Significant reduction in signal transducer and activator of transcription 3 (STAT3) phosphorylation in Clostridium difficile-infected
mice treated with anti-interleukin-22 (IL-22), anti-CD160 or anti-IL-22/CD160. Protein lysates from the colons (n = 8 in each group) of
untreated mice, CDI mice, CDI + anti-IL-22 mice, CDI + anti-CD160 mice, and CDI + anti-IL-22/CD160 mice from two sets of experiments
were used to evaluate the phosphorylation of STAT3 by immunoblotting. The panel on the left shows the image of the immunoblot for two
colons of each experimental group, and the bar graph on the right depicts the mean  SEM of the response for all eight colons in each group. A
P-value of ≤ 005 indicates a significant difference in STAT3 phosphorylation with the CDI mice and is marked with a ★. All four groups of
C. difficile-infected mice had significantly higher STAT3 phosphorylation than their untreated counterparts: CDI (P < 00001), CDI + anti-IL-22
(P = 0001), CDI + anti-CD160 (P < 00001), and CDI + anti-IL-22/CD160 (P = 0001) (not marked on the figure).
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and CDI + anti-IL-22/CD160 mice (Fig. 4d). Based on
these analyses, in CDI + anti-IL-22 mice, only two genes
were expressed at significantly lower levels than the CDI
mice; Reg3g (about fivefold less) and Ffar3 (about two-
fold less) (Fig. 4b). Furthermore, there was no signifi-
cant difference in gene expression between the CDI mice
and the CDI + anti-CD160 mice (Fig. 4c). By contrast,
CDI + anti-IL-22/CD160 mice had a significant reduc-
tion in the expression levels of 17 genes in comparison
to the CDI mice (Fig. 4d). These included the chemo-
kines Ccl4, Cxcl1 and Cxcl10; the cytokines Il1b, Tnfa,
Il10, Il12a, Il22 and Il25; the anti-microbial peptides
Defa1, Defb1 and Reg3g; as well as Arg1, Cldn2, Ffar3,
Mpo and Nod2.
Combined anti-IL-22/CD160 treatment reduces
neutrophil infiltration in response to C. difficile
infection
The decreased expression of Cxcl1, which plays a well-
documented role in neutrophil influx to the colons of
C. difficile-infected mice, and Mpo (Fig. 4d) in the colons
of CDI + anti-IL-22/CD160 mice led us to speculate that
these mice should have a lower neutrophilic infiltrate at
the site of infection than the three other groups of
C. difficile-infected mice, i.e. CDI mice, CDI + anti-IL-22
mice, and CDI + anti-CD160 mice. This premise was
assessed by two different approaches. First, haematoxy-
lin & eosin-stained colonic tissues (Fig. 5a) were scored
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Figure 4. Combined anti-interleukin-22 (IL-22)/CD160 treatment significantly alters the mucosal gene expression pattern in response to Clostrid-
ium difficile infection. Custom-made RT-PCR cards were used to evaluate gene expression levels in the colons (n = 5 in each group) of untreated
mice, CDI mice, CDI + anti-IL-22 mice, CDI + anti-CD160 mice, and CDI + anti-IL-22/CD160 mice from two sets of experiments. The panel
on the top left shows the significantly up-regulated genes in the colons of CDI mice in comparison to untreated mice (a). The remaining panels
show the change in expression of the genes depicted in (a) in CDI + anti-IL-22 mice (b); CDI + anti-CD160 mice (c); and CDI + anti-IL-22/
CD160 mice (d), as compared to CDI mice respectively (d also depicts Nod2, Cldn2 and Il10, which have significantly different expression levels
between CDI and CDI + anti-IL-22/CD160 mice but not between CDI and untreated mice). Each bar represents the mean  SEM of the relative
expression of the depicted gene. In each panel, ★ denotes a significant difference in expression levels between the specified groups of mice,
i.e. false discovery rate ≤ 005. It should be noted that a log2 scale is used for the graphs in (a), whereas the graphs in (b), (c) and (d) are on a
linear scale. Due to the intensity of its down-regulation, the Reg3g result in (d) is graphed separately.
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for neutrophilic inflammation. This showed a significant
reduction in neutrophilic infiltrate in CDI + anti-IL-22/
CD160 mice in comparison to CDI mice; by contrast,
neither CDI + anti-IL-22 mice, nor CDI + anti-CD160
mice showed a significant difference in neutrophil infil-
tration with CDI mice (Fig. 5b). To complement the
scoring outcome, we used flow cytometry to compare
the influx of neutrophils into the colons of CDI mice
and CDI + anti-IL-22/CD160 mice. As expected, CDI
mice showed a substantial influx of Ly6Ghigh cells, i.e.
neutrophils, into their colons. The CDI + anti-IL-22/
CD160 mice showed a clear reduction in the influx of
Ly6Ghigh cells in comparison to the CDI mice (Fig. 5c),
thereby confirming the histopathological findings.
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Figure 5. Combined anti-interleukin-22 (IL-22)/CD160 treatment reduces neutrophil infiltration in response to Clostridium difficile infection. (a)
Representative photomicrographs of haematoxylin & eosin-stained colonic sections from untreated mice, CDI mice, CDI + anti-IL-22 mice,
CDI + anti-CD160 mice and CDI + anti-IL-22/CD160 mice. The sections illustrate reduced inflammatory infiltration in the CDI + anti-IL-22/
CD160 mice in comparison to the CDI, the CDI + anti-IL-22, and the CDI + anti-CD160 groups of mice. Arrowheads point to cellular infiltrates
within each section. The top row of images are at 9100 original magnification, with the bar = 200 lm length. All other images are at 9400 ori-
ginal magnification, with the bar = 50 lm length. (b) Graph depicting the mean  SEM of the neutrophil infiltration scores for untreated mice,
CDI mice, CDI + anti-IL-22 mice, CDI + anti-CD160 mice and CDI + anti-IL-22/CD160 mice (n = 6 in each group) from two sets of experi-
ments. A P-value of ≤ 005 indicates a significant difference in neutrophil influx score with the CDI mice and is marked with a ★. All four
groups of C. difficile-infected mice had significantly higher neutrophil influx scores than their untreated counterparts: CDI (P < 00001),
CDI + anti-IL-22 (P < 00001), CDI + anti-CD160 (P < 00001), and CDI + anti-IL-22/CD160 (P = 002) (not marked on the figure). The dif-
ferences between both CDI + anti-IL-22 mice with CDI + anti-IL-22/CD160 (P = 0005), and CDI + anti-CD160 mice with CDI + anti-IL-22/
CD160 mice (P = 0.001) were also significant (not marked on the figure). (c) Decreased influx of neutrophils to the colons of CDI + anti-IL-22/
CD160 mice in comparison to CDI mice as assessed by flow cytometry. The histograms are concatenated overlays of three mice from each
group.
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Discussion
This study was conducted to examine the effects of IL-22
and CD160, and their potential interaction, on the
mouse mucosal response to C. difficile infection. Collec-
tively, the acquired data support the following main con-
clusions: (i) IL-22- and CD160-mediated signalling
together account for a significant fraction of the phos-
phorylated pool of STAT3 in the colons of C. difficile-
infected mice; and (ii) IL-22 and CD160 play an additive
role in mediating both the pro-inflammatory and pro-
survival aspects of the mouse mucosal response to C. dif-
ficile infection.
Anti-IL-22, anti-CD160 and combined anti-IL-22/
CD160 treatments all significantly reduced STAT3 phos-
phorylation in the colons of C. difficile-infected mice,
hence demonstrating that IL-22 and CD160 are together
responsible for a significant fraction of the colonic STAT3
phosphorylation in C. difficile infection. However,
although anti-IL-22, anti-CD160, and combined anti-IL-
22/CD160 treatments led to comparable reductions in
STAT3 phosphorylation, anti-CD160 treatment alone had
no significant effect on gene expression and anti-IL-22
treatment alone could significantly reduce the expression
levels of only two genes. By contrast, the combined use of
anti-IL-22 and anti-CD160, at the very same doses that
they were used individually, could significantly reduce the
expression of 17 genes, including those encoding pro-
inflammatory chemokines and cytokines, anti-microbial
peptides and pro-survival molecules. Interleukin-22 and
CD160 use different signalling pathways to phosphorylate
STAT3. In the case of IL-22, STAT3 phosphorylation is
through its recruitment to the IL-22 receptor,42 whereas
CD160 uses the nuclear factor-jB-inducing kinase
(NIK) to achieve this end.31 On this basis, we suggest
that altering the mucosal gene expression pattern in
C. difficile-infected mice at the level observed in the
CDI + anti-IL-22/CD160 mice would require the concur-
rent disruption of the pathways used by IL-22 and CD160
for STAT3 phosphorylation, something neither anti-IL-22
nor anti-CD160 can mediate on its own. The availability of
CD160/ mice in the future would allow us to further
explore this matter by comparing IL-22R/, CD160/
and IL-22R//CD160/ mice infected with C. difficile.
Interleukin-22 serves a critical role in promoting inflam-
mation, anti-microbial immunity and tissue repair at
mucosal surfaces.43–47 This is achieved by regulating the
expression of genes associated with chemotaxis, inflamma-
tion, anti-microbial immunity and tissue repair. STAT3
recruitment and its subsequent phosphorylation are essen-
tial for induction of IL-22 through all the pathways charac-
terized so far.46 Furthermore, the use of STAT3IEC-KO mice
has shown that IL-22-dependent mucosal wound healing is
contingent on STAT3 phosphorylation in intestinal epithe-
lial cells.48 The down-regulation of pro-inflammatory
chemokines and cytokines as well as anti-microbial
peptides, particularly Reg3g,49 in the colons of
CDI + anti-IL-22/CD160 mice, in conjunction with the
significant reduction of STAT3 phosphorylation in this
setting, provides further evidence for our previous asser-
tion18 that phosphorylated STAT3, IL-22 and RegIIIc are
an integral part of the host mucosal response to C. diffi-
cile infection.
Depending on the ligand it binds, the cell types involved
and the context of engagement, HVEM can activate co-
stimulatory or co-inhibitory signalling pathways.28–30 The
reduced induction of genes for pro-inflammatory chemo-
kines and cytokines, as well as anti-microbial peptides and
IL-25, which plays a role in attenuating tissue damage in
the gut,50 in CDI + anti-IL-22/CD160 mice strongly indi-
cates that IL-22 and HVEM-CD160 signalling act in
concert to mediate both the pro-inflammatory and pro-
survival aspects of the host mucosal response to C. difficile
infection.
It has been argued that the stereochemistry of LIGHT,
BTLA and CD160 binding to HVEM, as well as the cis or
trans nature of the interaction, would predict the behav-
iour of HVEM in respect of the T-cell response.51 How-
ever, the expression of HVEM and its ligands on a wide
range of haematopoietic and non-haematopoietic cells
makes this a more challenging task when trying to inter-
pret the outcome of multicellular interactions. This is of
particular relevance to the host response in the gut
because intestinal epithelial cells, which provide a point
of contact for enteric antigens and play a direct role in
mucosal immunity, constitutively express HVEM.21
Expression of HVEM on intestinal epithelial cells may
play a crucial role in engaging HVEM ligands on innate
and adaptive effector cells in the gut and regulating the
direction and intensity of the response. Theoretically,
BTLA, LIGHT and CD160 could all engage the intestinal
epithelial cell HVEM and act as its functional ligand dur-
ing C. difficile infection. However, a recent study of
mouse colonic intraepithelial lymphocytes has shown that
they express very low levels of BTLA and LIGHT mRNA
but high levels of CD160 mRNA.31 This leaves CD160 as
the most plausible ligand to trigger HVEM signalling on
colonic epithelial cells in the course of C. difficile
infection. The current study shows that, in C. difficile
infection, CD160 acts in a co-stimulatory capacity. The
co-stimulatory role of CD160 is infrequent but docu-
mented. In vitro findings with human T cells had first
raised this possibility.27 More recent studies have proven
CD160’s co-stimulatory role in two different in vivo mod-
els.31,52 Given that the host response to C. difficile infec-
tion includes both pro-inflammatory and pro-survival
elements, future efforts will need to determine whether
the pro-inflammatory and pro-survival effects of HVEM/
CD160 signalling in this infection involves one or more
subsets of intraepithelial lymphocytes.
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While treatment with either anti-IL-2245 or anti-
CD16031 alone will affect the course of Citrobacter roden-
tium infection in mice, treating C. difficile-infected mice
with a specified, and previously documented, dose of
either anti-IL-22 or anti-CD160 had a limited (anti-
IL-22) or non-existent (anti-CD160) significant effect on
the gene expression pattern for the evaluated genes, i.e.
two genes significantly reduced in the CDI + anti-IL-22
mice and none significantly changed in the CDI + anti-
CD160 mice. Although the anti-CD160 clone used in our
experiments (clone CNX46-3)53 is identical to the one
used in the Citrobacter rodentium infection model,31 the
anti-IL-22 antibody administered in that model (clone
8E11)45 is different from the one used in our study (clone
IL22JOP). Therefore, in the case of anti-IL-22, it could be
argued that the difference in outcome between the two
infections may simply reflect the distinct effector func-
tions of the two different anti-IL-22 clones. Given that
the anti-IL-22 clone used in the current study has been
used successfully to affect the severity of inflammation in
an in vivo model of skin inflammation,54 its limited effect
in C. difficile-infected mice cannot be attributed to its
lack of biological activity, but it would not be implausible
to contend that the dose and duration of its use may not
be ideal for an optimal response in the gut. The alterna-
tive hypothesis, which we favour, is that the need for the
concomitant use of anti-IL-22 and anti-CD160 to affect
the gene expression pattern or histopathological outcome
in mice infected with C. difficile 630 is due to an inherent
difference in the biology of Citrobacter rodentium and
C. difficile infections in mice. Our findings that the use of
the two antibodies together, at the very same doses that
they were used individually, led to a significant reduction
in 17 of the 45 evaluated genes and a decrease in neutro-
phil influx to the site of infection, provides strong empir-
ical support for this hypothesis.
As discussed in detail in our previous work,18 the genes
induced in response to C. difficile infection fall into three
broad categories: first, chemokines, which play a pivotal
role in recruiting effector cells of the innate immune system
to the site of infection; second, pro-inflammatory cyto-
kines, which mediate inflammatory effector functions at
the site of infection and in turn contribute to the up-regu-
lation of chemokines such as Cxcl1, Ccl2, Cxcl9 and Cxcl10;
and third, Il22 and anti-microbial peptides, which mediate
the host’s efforts to maintain epithelial integrity. The opti-
mal outcome of these gene up-regulations is to contain the
C. difficile-induced inflammation and to minimize mucosal
damage by promoting epithelial homeostasis.18,55
The CDI + anti-IL-22/CD160 mice show a simulta-
neous and significant reduction in the expression of a
number of chemokines, pro-inflammatory cytokines and
anti-microbial peptides. This could arguably reflect the
host’s effort to curtail the extent of host-mediated immu-
nopathology. Under this scenario, the lower intensity of
inflammation would incur less host-mediated damage at
the site of infection, therefore decreasing the required
level of homeostatic activity for restoring epithelial integ-
rity. In this study, the observed early histopathological
and flow cytometric manifestation of anti-IL-22/CD160
treatment in C. difficile-infected mice is anti-inflamma-
tory. Based on the prolonged course of infection with
C. difficile 630,33 we believe that the histopathological epi-
thelial manifestation of anti-IL-22/CD160’s effect on
expression levels of Reg3g, Il25, etc., as well as its poten-
tial effect on bacterial load, would require a longer course
of infection and antibody treatment than was undertaken
in the current study; this will be the first focus of our
future efforts.
Taking our cue from the work done on sustaining
eIF2a phosphorylation in prion-induced neurodegenera-
tion,56 we had argued that manipulating common bio-
chemical pathways, rather than disease- and pathogen-
specific approaches, could potentially be of therapeutic
benefit across a spectrum of conditions with analogous
and/or shared pathophysiologies.18 Our current findings
with the combined use of anti-IL-22/CD160 in C. difficile
infection, together with the report on the contribution of
HVEM/CD160 to host defence against Citrobacter roden-
tium infection in the gut and Streptococcus pneumoniae
infection in the lung,31 gives further credence to this con-
cept in the context of infection and could serve as a point
of departure for a new approach for affecting an infec-
tion’s outcome.
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